section name header

Evidence summaries

Mirabegron for Urinary Incontinence and Overactive Bladder

Mirabegron is effective for urge or mixed urinary incontinence and overactive bladder compared with placebo, and appears to have fewer adverse effects than anticholinergics. Level of evidence: "A"

Mirabegron is recommended for women with urinary incontinence or overactive bladder who do not get enough relief from pelvic floor muscle training.

The recommendation is strong because of large effect size for patient important outcomes. Mirabegron is only recommended as second-line treatment compared to pelvic floor muscle training because of uncertainty in the balance of benefits and harms, but is preferred over ancholinergics because of fewer adverse effects.

Summary

A meta-analysis 1 included 8 studies with a total of 10 248 subjects. Mirabegron at both doses of 50 mg and 100 mg, and and tolterodine 4 mg were significantly associated with the reduction of incontinence episodes per 24 h, reduction of mean number of micturitions per 24 h, increase of voided volume and reduction of urgency episodes per 24 h, compared to a placebo. Both mirabegron 50 mg and mirabegron 100 mg were associated with a significant reduction of nocturia episodes when compared with a placebo. Furthermore, mirabegron 50 mg showed a slightly, but significantly, better efficacy than tolterodine 4 mg in the improvement of nocturia episodes. However, mirabegron 100 mg showed a slight trend toward an increased risk of hypertension (odds ratio 1.41; P = 0.08) and cardiac arrhythmia (odds ratio 2.18; P = 0.06).

A network meta-analysis 2 included 64 studies with a total of 46 666 subjects. Mirabegron 50mg was significantly more efficacious than placebo for all efficacy endpoints. Comparable overall efficacy was observed for mirabegron 50mg versus most active treatments, but solifenacin 10mg monotherapy and solifenacin 5mg plus mirabegron 25 or 50mg in combination were more efficacious for some/all outcomes. Mirabegron 50mg was significantly better tolerated regarding dry mouth, constipation, and urinary retention than 21/22, 9/20, and 7/10 active comparators, respectively; similar overall tolerability was observed between mirabegron 50mg and all treatments (including placebo) for the remaining endpoints.

Clinical comments

Note

Date of latest search: 2020-03-08

References

  • Sebastianelli A, Russo GI, Kaplan SA et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine. Int J Urol 2018;25(3):196-205. [PubMed]
  • Kelleher C, Hakimi Z, Zur R et al. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Eur Urol 2018;74(3):324-333. [PubMed]

Primary/Secondary Keywords